# Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

> **NCT04523246** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Oklahoma** · enrollment: 217 (actual)

## Conditions studied

- Herpes Zoster
- Allergy and Immunology
- Corona Virus Infection

## Interventions

- **BIOLOGICAL:** SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT04523246
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2021-12-30
- **Final completion:** 2023-05-19
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523246, "Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04523246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*